Publications by authors named "S Accomando"
: An increasing number of studies have reported liver involvement in both children and adults with celiac disease (CD). This often manifests as isolated hypertransaminasemia or hepatic steatosis (HS). The aim of this study was to define the prevalence of hypertransaminasemia and HS in a pediatric population with CD before starting a gluten-free diet (GFD) and to analyze how the introduction of a GFD could modify this condition.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers isolated nanovesicles from individuals with chronic diarrhea, examining the effects of a specific probiotic mix over 60 days on Tryptophan 2,3-dioxygenase 2 (TDO 2) levels and cellular stress responses.
- * Results indicated that probiotics improved TDO 2 levels and serotonin receptor expression, preserved intestinal barrier function, and exhibited stress-reducing effects, supporting the link between gut health and brain function.
Background: The aim of this study is to compare two groups of celiac patients: the first one, in which diagnosis was based on a "biopsy sparing" approach according to the 2012 ESPGHAN criteria, and the second one, based on the biopsy approach like the one of the 1991 Revised Criteria, in order to find relevant difference for sex, M/F ratio, age at diagnosis, clinical features at the onset, presence and prevalence of concomitant autoimmune disorders.
Methods: Our study involves 61 patients having the Celiac Disease (CD) onset from February 2013 to February 2020. The 32 patients who received diagnosis according "biopsy sparing" criteria were enrolled in group (1) The 29 patients who received diagnosis by duodenal biopsy were enrolled in group (2) Prevalence of comorbidities was analysed through chi-square test.
Article Synopsis
- The study investigates the effectiveness and safety of adalimumab biosimilar (ADL-BioS) for treating pediatric patients with inflammatory bowel disease (IBD), as data on this topic is limited.
- It involved 41 pediatric IBD patients treated with ADL-BioS from 2019 to 2021, measuring outcomes such as clinical remission at 14 and 52 weeks, treatment persistence, and adverse events.
- Results showed that approximately 71% achieved remission, treatment persistence was high at 85.4%, and only a small percentage experienced adverse events, suggesting that ADL-BioS is an effective and safe option for pediatric IBD patients.
Background: Allergic disease, including food allergies (FA)s, has been identified as a major global disease. The first 1000 days of life can be a "window of opportunity" or a "window of susceptibility", during which several factors can predispose children to FA development. Changes in the composition of the gut microbiota from pregnancy to infancy may play a pivotal role in this regard: some bacterial genera, such as and , seem to be protective against FA development.
View Article and Find Full Text PDF